Dimensional Fund Advisors LP Has $242.57 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Dimensional Fund Advisors LP trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 586,701 shares of the company’s stock after selling 16,017 shares during the period. Dimensional Fund Advisors LP’s holdings in IDEXX Laboratories were worth $242,569,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Hurley Capital LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at $29,000. Rialto Wealth Management LLC bought a new stake in IDEXX Laboratories in the fourth quarter valued at about $30,000. Retirement Wealth Solutions LLC acquired a new position in IDEXX Laboratories in the fourth quarter valued at about $31,000. Kestra Investment Management LLC bought a new position in IDEXX Laboratories during the fourth quarter worth about $38,000. Finally, Crews Bank & Trust acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $41,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $406.65 on Tuesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The business has a 50-day moving average of $421.36 and a 200-day moving average of $429.98. The stock has a market capitalization of $32.95 billion, a price-to-earnings ratio of 38.11, a PEG ratio of 3.41 and a beta of 1.50. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $548.88.

Analyst Ratings Changes

A number of analysts recently weighed in on IDXX shares. Barclays increased their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Morgan Stanley dropped their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Piper Sandler increased their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 12th. Finally, Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a research note on Monday, April 14th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $523.75.

Insiders Place Their Bets

In other news, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.